Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

793 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. Uemura N, et al. Among authors: fujikawa k. Cancer Chemother Pharmacol. 2017 Oct;80(4):707-713. doi: 10.1007/s00280-017-3404-8. Epub 2017 Aug 28. Cancer Chemother Pharmacol. 2017. PMID: 28849257 Clinical Trial.
Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: fujikawa k. Gastric Cancer. 2017 May;20(3):517-526. doi: 10.1007/s10120-016-0633-1. Epub 2016 Aug 23. Gastric Cancer. 2017. PMID: 27553665 Clinical Trial.
Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J. Ohnuma H, et al. Among authors: fujikawa k. Cancer Sci. 2018 Nov;109(11):3554-3563. doi: 10.1111/cas.13772. Epub 2018 Sep 25. Cancer Sci. 2018. PMID: 30137686 Free PMC article. Clinical Trial.
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Saka H, Kitagawa C, Kogure Y, Takahashi Y, Fujikawa K, Sagawa T, Iwasa S, Takahashi N, Fukao T, Tchinou C, Landers D, Yamada Y. Saka H, et al. Among authors: fujikawa k. Invest New Drugs. 2017 Aug;35(4):451-462. doi: 10.1007/s10637-016-0416-x. Epub 2017 Jan 10. Invest New Drugs. 2017. PMID: 28070720 Free PMC article. Clinical Trial.
A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer.
Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, Fujikawa K, Nobuoka T, Okamoto K, Miyamoto H, Muguruma N, Takemasa I, Takayama T. Sato Y, et al. Among authors: fujikawa k. Cancer Chemother Pharmacol. 2019 Jan;83(1):161-167. doi: 10.1007/s00280-018-3719-0. Epub 2018 Nov 7. Cancer Chemother Pharmacol. 2019. PMID: 30406285 Clinical Trial.
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Yonemori K, et al. Among authors: fujikawa k. Cancer Chemother Pharmacol. 2016 Sep;78(3):525-31. doi: 10.1007/s00280-016-3106-7. Epub 2016 Jul 15. Cancer Chemother Pharmacol. 2016. PMID: 27422301 Free PMC article. Clinical Trial.
Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Fukuya A, Okamoto K, Miyamoto H, Muguruma N, Fujikawa K, Takahashi Y, Takayama T. Sagawa T, et al. Among authors: fujikawa k. Sci Rep. 2020 Nov 13;10(1):19815. doi: 10.1038/s41598-020-76756-1. Sci Rep. 2020. PMID: 33188279 Free PMC article.
793 results